Article and Video CATEGORIES

Cancer Journey

Search By

Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC
Fri, 02/05/2016 - 06:00
Author
GRACE Videos and Articles
Image
GRACE Cancer Video Library - Lung

 

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

 

Transcript

Let’s start by defining, or explaining, the heterogeneity of stage III disease. In my mind, the two major types of stage III patients are those that have lesions that start to invade structures, and certainly T3 lesions that may invade the chest wall, the pericardium, the diaphragm — associated with N1 disease, are stage III disease but they are generally considered resectable. Then, we have those lesions that are more invasive and invade vital structures and are so-called T4 lesions, which for the most part, are not resectable, with some rare exceptions with regard to resection of vital structures and reconstruction and those sorts of issues.

The second major group is the development of mediastinal lymph node involvement by the cancer. The mediastinum is full of lymph nodes, they’re obviously the major draining site for many cancers. We divide the mediastinal nodes into N2 nodes, or nodes that are on the same side as the cancer, versus N3 nodes that are on the opposite side of the cancer.

You can think of the range of patients that you would see, either with larger invasive disease, or disease involving mediastinal lymph nodes. Another area is where patients have multiple nodules in either the same lobe, or a different lobe on the same side, and those would be the difference between T3 and T4 lesions, which would also be categorized within stage III disease.

So, you can see that this patient population encompasses a wide range of patients, each of which demands, really, a different approach and an individualized approach based on what type of subset you’re in, with regard to stage III disease.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Mandarin LCVL
Video
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit: https://www.youtube.com/playlist?list=PLWsyUmdjLXhGnSxobmz4CBP3pxAj7nDa…;  
Image
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
Article
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Image
Blood Cancer OncTalk
Video
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

JOIN THE CONVERSATION
Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
Concerned
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29